• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Daniel Mark James

    10/21/25 4:05:06 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Daniel Mark James

    (Last) (First) (Middle)
    C/O ATOSSA THERAPEUTICS, INC.
    10202 5TH AVENUE NE SUITE 200

    (Street)
    SEATTLE WA 98125

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/14/2025
    3. Issuer Name and Ticker or Trading Symbol
    ATOSSA THERAPEUTICS, INC. [ ATOS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Mark James Daniel 10/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Daniel Mark James

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    10/21/25 4:10:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Daniel Mark James

    3 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    10/21/25 4:05:06 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/28/25 4:00:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    4/11/24 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    SEC Filings

    View All

    Atossa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    10/14/25 7:50:28 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    9/26/25 5:12:32 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    9/8/25 8:36:48 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

    Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS SEATTLE, Oct. 21, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of California, San Francisco and Principal Investigator of RECAST™, will speak at the Early Detection Research Conference in Portland, OR, about the Company's collaborative work in the RECAST platform trial fo

    10/21/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics to Present at the Maxim Growth Summit 2025

    Invites New Investors to Learn More About $ATOS SEATTLE, Oct. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces that Chairman and Chief Executive Officer Steven Quay, M.D., Ph.D. will participate in the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel, New York City. Dr. Quay will also be available for one-on-one investor meetings during the conference. Why attend or follow along? Clear strategy &

    10/15/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

    25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science

    10/14/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Financials

    Live finance-specific insights

    View All

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

    Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

    5/13/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    3/25/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

    25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science

    10/14/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

    Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs SEATTLE, Oct. 1, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS, ", Atossa", or the ", Company", )), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Janet R. Rea, MSPH to its newly created position Senior Vice President, R&D.  Ms. Rea brings more than two decades of strategic research and clinical development expertise, with a success record for regulatory approvals, to oversee late-stage (Z)-endoxifen programs with ne

    10/1/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

    SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS, "Atossa" or the "Company")), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in emerging and established growth company strategies that enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences. Dr. Steven Quay, Chairman and CEO of Atossa, commented, "Ou

    9/17/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/12/24 1:32:30 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/4/24 11:27:58 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    2/9/23 11:07:47 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care